IOmet, Merck deal

Merck acquired immuno-oncology company IOmet. Merck will gain IOmet’s preclinical pipeline of inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1) and tryptophan 2,3-dioxygenase ( TDO2; TDO) as well ...